A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Hosted on MSN20d
Silexion reports breakthrough in KRAS cancer therapyThe drug is designed to inhibit several oncogenic KRAS mutations, which are prevalent in various human cancers. Mitchell Shirvan, Ph.D., Chief Scientific Officer of Silexion, expressed enthusiasm ...
Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...
Hosted on MSN28d
FDA approves Amgen’s combo therapy for colorectal cancerAmgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination has received approval from the US Food and Drug Administration (FDA) to treat adults with Kirsten rat sarcoma virus gene (KRAS) ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...
Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
"At Edible Garden, sustainability is more than just a goal—it is a core principle that guides everything we do," said Jim Kras, CEO of Edible Garden. "The introduction of our curb-side recyclable pot ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results